Skip to content

Identification and analysis of relevant attributes for choices for liver cancer therapies.

Identification and analysis of relevant attributes for choices for liver cancer therapies. - IRALCT

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00013304
Enrollment
1029
Registered
2017-11-16
Start date
2017-11-16
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22.9 C78.7 C24.9

Interventions

Group 1: A computer-based survey will be conducted with participants to identify relevent attributes of liver cancer therapies. Each group will edit the same questionaire. The participants were inter

Sponsors

Medizinische Hochschule Hannover
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: The study includes full aged liver cancer patients from Hannover Medical School who undergo a minimal invasive therapy e.g. thermal ablation, selective chemotherapy/radiotherapy, and surgical treatment. Moreover, we interview physicians stationed in the gastroenterology and medical nonprofessionals

Exclusion criteria

Exclusion criteria: Underage persons, critically ill and unstable patients, and patients who have participated in another study within the last 30 days are excluded from the study. Another exclusion criterion is to terminate the survey upon request. In order to determine the eligibility of a patient, the treating physician will ensure the examination of the medical exclusion criteria.

Design outcomes

Primary

MeasureTime frame
The main study aims to reveal the patients’ preferences for specific treatment options that, if medically justified, might be taken into account in future decision-making processes by medical professionals. The results can improve medical treatment in terms of evidence-based medicine and shared decision-making, and thereby increase the satisfaction (welfare) of both patients and physicians.

Secondary

MeasureTime frame
The aim of the preliminary study is to identify the relevant attributes of liver cancer therapies influencing the choice of therapy.

Countries

Germany

Contacts

Public ContactBennet Hensen

Medizinische Hochschule Hannover

hensen.bennet@mh-hannover.de05115323421

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 13, 2026